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PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United
States. This study was aimed at evaluating the efficacy of AR-42 (formerly OSU-HDAC42), a novel histone
deacetylase (HDAC) inhibitor currently in clinical trials, in suppressing tumor growth and/or cancer-induced muscle
wasting in murine models of PDAC. EXPERIMENTAL DESIGN: The in vitro antiproliferative activity of AR-42 was
evaluated in six human pancreatic cancer cell lines (AsPC-1, COLO-357, PANC-1, MiaPaCa-2, BxPC-3, SW1990).
AsPC-1 subcutaneous xenograft and transgenic KP fl/flC (LSL-KrasG12D;Trp53flox/flox;Pdx-1-Cre) mouse models of
pancreatic cancer were used to evaluate the in vivo efficacy of AR-42 in suppressing tumor growth and/or muscle
wasting. RESULTS: Growth suppression in AR-42–treated cells was observed in all six human pancreatic cancer
cell lines with dose-dependent modulation of proliferation and apoptotic markers, which was associated with the
hallmark features of HDAC inhibition, including p21 upregulation and histone H3 hyperacetylation. Oral
administration of AR-42 at 50 mg/kg every other day resulted in suppression of tumor burden in the AsPC-1
xenograft and KP fl/flC models by 78% and 55%, respectively, at the end of treatment. Tumor suppression was
associated with HDAC inhibition, increased apoptosis, and inhibition of proliferation. Additionally, AR-42 as aThe Ohio State University Wexner Medical Center and Comprehensive Cancer Center
(T.B.S.), and grant # MOST 105-2321-B-001-064 from the Team of Excellent
Research Program of the Ministry of Science and Technology, Taiwan (C.S.C.).Na-
tional Institutes of Health grant T32OD010429-14 (S.E.H.)National Institutes of
Health grant P30 CA016058, which supports, in part, the Target Validation Shared
Resource at The Ohio State University Comprehensive Cancer Center.
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766 Suppression of Tumor Growth and Muscle Wasting Henderson et al. Neoplasia Vol. 18, No. 12, 2016single agent preserved muscle size and increased grip strength in KP fl/flC mice. Finally, the combination of AR-42
and gemcitabine in transgenic mice demonstrated a significant increase in survival than either agent alone.
CONCLUSIONS: These results suggest that AR-42 represents a therapeutically promising strategy for the
treatment of pancreatic cancer.
Neoplasia (2016) 18, 765–774Introduction
Pancreatic cancer is the third leading cause of cancer death in the
United States [1]. Despite advances in chemotherapeutic regimens,
prognosis remains dismal, with a 5-year survival of less than 7% for all
stages [1] and a 5-year survival rate of only 2% among patients with
metastatic disease [2]. Surgical resection followed by adjuvant therapy
offers the only chance for a cure; however, less than 15% of patients
present with resectable disease [3]. Cytotoxic chemotherapy with
gemcitabine has been the standard of care and the backbone of
experimental regimens in advanced pancreatic cancer for over a
decade [4]. More recent studies have identified the benefit of
nab-paclitaxel in combination with gemcitabine in marginally
improving the median overall survival to 8.5 months versus 6
months with gemcitabine alone, and similar results were found in
metastatic pancreatic cancer using a 5-flurouracil, oxaliplatin, and
irinotecan regimen [2,5]. However, the overall poor median survival
for this disease persists because of inherent or acquired drug resistance
to cytotoxic agents. Therefore, there is an unmet need to develop
novel therapies to improve clinical outcomes in pancreatic cancer.
The organization of the genome is defined by chromatin structure
and regulates whether genes are actively transcribed or silenced. The
epigenetic mechanisms that regulate chromatin structure and thus
influence gene expression include methylation of cytosine bases in
DNA and posttranslational modifications of histone proteins [6].
These histone modifications include acetylation, which is associated
with open, actively transcribed chromatin, and deacetylation, which is
associated with closed, or inactive, heterochromatin. The acetylation
and deacetylation of histones are mediated by histone acetyltransfer-
ases and histone deacetylases (HDACs), respectively [6]. HDACs are
often overexpressed in various types of cancer, resulting in increased
proliferation and dedifferentiation [6,7], and their pharmacologic
inhibition has been shown to have potent anticancer effects, including
growth arrest, differentiation and apoptosis, in multiple types of
human cancer cells [7,8], including pancreatic cancer. For example,
trichostatin A [9] and suberoylanilide hydroxamic acid (SAHA,
vorinostat, Zolinza) have been shown to inhibit the growth of various
pancreatic cell lines alone and in combination with gemcitabine
[10,11], and in vitro synergism was reported for the combination of
chidamide, a novel benzamide HDAC inhibitor, and gemcitabine in
inducing cell growth arrest and apoptosis in pancreatic cancer cell
lines [12].
AR-42 is a novel HDAC inhibitor that was developed in our
laboratory and is currently in Phase I/IB trials in both hematological
malignancies and solid tumors [13]. The in vivo antitumor efficacy of
oral AR-42 has been demonstrated by its ability to suppress the
growth of various types of xenograft tumors in nude mice, including
those of prostate [14], liver [15], ovary [16], and mast cells [17], as
well as to block prostate carcinogenesis in a transgenic mouse model[18]. Evidence suggests that AR-42 mediates antitumor effects
through both histone-dependent and -independent mechanisms.
Aside from epigenetic activation of tumor suppressor genes, AR-42
has been shown to facilitate Akt dephosphorylation via phosphatase 1
(PP1) activation [19], to inhibit the gp130/Stat3 pathway [20], to
inactivate the DNA repair machinery for double-strand breaks via
Ku70 acetylation [21], to downregulate constitutively active Kit [17],
and to facilitate the proteasomal degradation of topoisomerase IIα
[22]. The safety profile of AR-42 has previously been established in
the mouse prostate (TRAMP) model, where mild hematologic
alterations and testicular degeneration were seen and found to be
completely reversible following discontinuation of drug [18].
In addition to the aforementioned tumor-suppressive effects, the
ability of AR-42 to reverse cancer-induced muscle wasting in the
colon-26 carcinoma and Lewis lung carcinoma models of cachexia is
noteworthy [23]. Cachexia, characterized by severe weight loss due to
depletion of skeletal muscle mass that is not reversible by
conventional nutritional support [24], is prevalent among pancreatic
cancer patients [25] and contributes significantly to the morbidity
and mortality of this disease. Based on these data, we hypothesized
that AR-42 might also ameliorate the development of cachexia in
PDAC in addition to suppressing tumor growth.
In the present study, we examined the in vitro effects of AR-42 in
six human pancreatic cancer cell lines. We show that AR-42
demonstrates potent antiproliferative effects associated with
dose-dependent modulation of apoptosis, HDAC inhibition, and
decreased proliferation and G2 cell cycle arrest. The in vivo efficacy of
AR-42 was demonstrated by suppression of tumor growth in an
AsPC-1 tumor xenograft mouse model and a KP fl/flC transgenic
mouse model of pancreatic cancer. Tumor suppression in the
xenograft tumors was associated with HDAC inhibition, increased
apoptosis, and inhibition of proliferation. In addition, AR-42 as a
single agent maintained muscle fiber size and increased grip strength
in transgenic mice. Furthermore, the combination of AR-42 and
gemcitabine showed a significant improvement in survival over the
use of either agent alone. These results suggest that the use of AR-42
represents a therapeutically promising strategy for the suppression of
tumor growth in pancreatic cancer.
Materials and Methods
Reagents
AR-42 was a kind gift from Arno Therapeutics, Inc. (Flemington,
NJ). For in vitro experiments, a stock solution of AR-42 was prepared
in dimethyl sulfoxide (DMSO) and diluted in a 10%
serum-containing culture medium for treatment of cells (final
concentration of DMSO b0.1%). For in vivo experiments, AR-42
was prepared as a suspension in a vehicle [10% DMSO, 0.5%
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water] for oral administration to xenograft-bearing athymic nude
mice. Antibodies and primer sequences are listed in the Supplemen-
tary Information.
Cell Culture
Human pancreatic cancer cell lines PANC-1, AsPC-1, BxPC-3,
SW1990, and MiaPaCa-2 were purchased from American Type
Culture Collection (Manassas, VA), which authenticates human cell
lines in their collection using short tandem repeat analysis, and were
used in fewer than 6 months of continuous passage. The COLO-357
human pancreatic cell line was obtained from the Tissue Culture
Shared Resource of Georgetown Lombardi Comprehensive Cancer
Center (Washington, D.C.) where DNA fingerprinting was
performed for authentication. PANC-1, SW1990, BxPC-3,
AsPC-1, and COLO-357 cells were cultured in RPMI 1640 medium
(Gibco, Life Technologies, Grand Island, NY) supplemented with
10% fetal bovine serum (FBS; Gibco, Life Technologies) and 1%
penicillin-streptomycin. MiaPaCa-2 cells were cultured in Dulbecco's
modified Eagle's medium (DMEM; Gibco, Life Technologies)
supplemented with 10% FBS and 1% penicillin-streptomycin. All
cells were cultured at 37°C in a humidified incubator containing 5%
CO2. Cells in log phase growth were harvested by trypsinization for
use in various assays and in vivo studies.
Analyses of Cell Viability and Cell Cycle
Cell viability was assessed with 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays as described
previously [14]. Cell cycle analysis was performed by using standard
methods as described previously [26]. Further experimental details are
included in the Supplementary Information.
Immunoblotting
Western blot analyses of AR-42– and vehicle-treated pancreatic
cancer cells were performed as previously reported [19]. Briefly, 3 ×
105 cells were seeded onto 6-cm plates in 10% FBS–supplemented
medium. After 24 hours, cells were treated with AR-42 for 48 hours
in the same medium and then suspended in SDS lysis buffer,
sonicated, and boiled for 10 minutes. Equivalent amounts of protein
lysates were resolved by SDS-PAGE (10%-12%); transferred to
nitrocellulose membrane; and immunoblotted for phospho-Akt
(Ser473), Akt, PCNA, cleaved PARP, BAK, BCL-XL, c-Myc, cyclin
B1, p21, acetylated histone H3, and histone H3. Western blot
analysis of equivalent amounts of muscle protein lysates from KP fl/flC
mice were resolved by SDS-PAGE as described above and
immunoblotted for Murf-1, acetylated histone H3, and histone H3.
AsPC-1 Xenograft Tumor Model
Female athymic nude mice (5 weeks of age) were obtained from the
Target Validation Shared Resource of The Ohio State University
Comprehensive Cancer Center. Each mouse received a subcutaneous
injection of 1 × 106 AsPC-1 cells in a total volume of 0.1 ml of
serum-free medium containing 50% Matrigel (BD Biosciences, San
Jose, CA) under isoflurane anesthesia. As the tumors became
established (90.7 ± 9.4 mm3 [mean, SD]), the mice were randomly
divided into two groups (n = 7) that received the following treatments
by oral gavage every other day: vehicle (0.5% methylcellulose/0.1%
Tween 80/10% DMSO in water) and AR-42 at 50 mg/kg of body
weight. Tumors were measured weekly with calipers, and theirvolumes were calculated with a standard formula: width2 × length ×
0.52. Body weights were measured weekly. At termination, tumors
were harvested, snap-frozen in liquid nitrogen, and stored at −80°C
until biomarker analysis by Western blotting. Procedures were
performed in accordance with protocols approved by the Institutional
Animal Care and Use Committee of The Ohio State University.
Genetically Engineered Mouse Model of Pancreatic Cancer
To assess the effects of AR-42 on tumor growth, cancer-induced
muscle wasting, and gemcitabine sensitivity in a spontaneous tumor
model of pancreatic cancer, each of the KP fl/flC (LSL-Kras-
G12D;Trp53flox/flox;Pdx-1-Cre) mice was verified by genotyping
PCR and screened for the presence of pancreatic tumors by
ultrasound at 4 weeks of age, and randomized to groups (n = 7-16)
that received the following treatments: (a and b) AR-42 alone (25 and
50 mg/kg, q2d, p.o. by gavage); (c and d) gemcitabine alone (40 and
80 mg/kg, twice weekly, i.p.); (e) AR-42 (25 mg/kg, q2d, p.o.) plus
gemcitabine (40 mg/kg, twice weekly, i.p.); and (f) vehicles (0.5%
methylcellulose/0.1% Tween 80/10% DMSO in water, p.o., and
physiological saline, i.p.). AR-42 and gemcitabine were administered
continuously for the entire study. Tumor volumes were calculated
from biweekly ultrasound measurements with a Vevo 770 instrument
and a 60-MHz probe (Visualsonics Inc. Ontario, Canada) in
anesthetized mice. At terminal sacrifice, tumors were harvested and
bisected with one piece preserved in RNAlater reagent (Qiagen,
Valencia, CA) for RNA and biomarker analyses and the other piece
fixed in formalin and embedded in paraffin for histological and
immunohistochemical analysis. Hindlimb muscles (gastrocnemius,
quadriceps, tibialis anterior) were also harvested for evaluation of
muscle fiber size, as described below in “Grip Strength Analysis and
Cross-Sectional Area of Muscle Fibers.” All experimental procedures
using live animals were conducted in accordance with protocols
approved by The National Cheng Kung University Institutional
Animal Care and Use Committee.
Immunohistochemical Analysis
All tissues were examined via light microscopy using an Olympus
Model BX53 microscope (Olympus Corp., Tokyo, Japan). The
hematoxylin and eosin (H&E) staining of pancreatic tumor sections
from each KP fl/flC mouse was performed according to standard
procedures. To evaluate pancreatic epithelial proliferation, 5-mm-
thick, paraffin-embedded tissue sections of the tumorous pancreas
were immunostained for pan-cytokeratin AE1/AE3 (GTX26401,
GeneTex, Hsinchu City, Taiwan) applied at the dilution of 1:500.
The immunohistochemistry (IHC) staining protocol used the
EnVision Detection Systems Peroxidase/DAB staining technique
per manufacturer's instructions (K5007; Dako, Glostrup, Denmark).
Staining is completed by a 5- to 10-minute incubation with
3-amino-9-ethylcarbazole chromogen, which results in a pink-
colored precipitate at the antigen site.
Opal Multiplexed IHC
Pancreatic tumors from KPCmice were formalin fixed and paraffin
embedded for Opal multiplexed IHC staining. Pancreatic tissue
sections of 5 μm thickness were deparaffinized, rehydrated and the
antigen retrieval were performed in microwave to boil for 25 minutes
using Opal antigen retrieval buffer at pH = 6.0 (Opal 4-color IHC
Kit, NEL79400, Perkin Elmer, Inc., Waltham, MA). All tissue
sections were blocked with antibody diluent (Dako, S0809,
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then incubated with primary antibodies (Ki67 and pan-cytokeratin
[GeneTex Inc., Hsinchu City, Taiwan] and caspase-3 [Santa Cruz
Biotechnology, Inc. Dallas, TX]) overnight at 4°C followed by
incubation with HRP-conjugated secondary antibodies (Dako,
K5007, Carpinteria, CA) for 10 minutes at room temperature. A
50× diluted TSA Plus Working Solution (Opal 4-color IHC Kit,
NEL79400) was added to slides to incubate for 10 minutes at room
temperature. Slides were stripped using microwave, blocked, and then
incubated with primary antibodies, HRP-conjugated secondary
antibodies, and TSA Plus Working Solution to amplify signals as
described above. All primary antibodies were diluted with antibody
diluent. DAPI was used to stain cell nuclei. Positive signals were
quantified using ImageJ software with the same threshold. Three 20×
individual fields for each sample were analyzed, and results were
expressed as percentage per visual field.
Grip Strength Analysis and Cross-Sectional Area of Muscle Fibers
Forelimb grip strength was measured as previously described [23]
using a Digital Grip Strength Meter (Columbus Instruments,
Columbus, OH). For each mouse, grip strength was defined as the
average of nine measurements. For evaluation of muscle fiber size,
fresh frozen muscle tissues were prepared according to standard
procedures. Essentially, the gastrocnemius, quadriceps, and tibialis
anterior muscles were harvested by dissection under a Leica Wild
M650 surgical microscope (Leica Microsystems [SEA] Pte Ltd.,
Singapore, Singapore) within 10 minutes after mice were sacrificed.
The freshly isolated muscle tissues were rinsed with FSC 22 tissue
freezing medium (Leica Microsystems [SEA], Pte Ltd., Singapore,
Singapore) and placed into isopentane that was precooled in liquid
nitrogen. The resulting frozen muscle cores were stored at −80°C.
Cryosections of muscle cores were cut on a cryostat microtome
(CM3050S, Leica Microsystems), paraffin embedded, and then H&E
stained. Image J software [27] was used to calculate the cross-sectional
areas of muscle fibers in three independent 400× fields in each muscle
tissue section. Data were collected from 150 fibers from multiple
sections of 6 mice per group.
Statistical Analysis
All analyses were performed at the OSU Center for Biostatistics by
using SAS 9.4 (SAS, Inc., Cary,NC).Multiplicity was adjusted by using
Holm's method to control the type I familywise error rate at 0.05.
Analysis of variance (ANOVA) was used to analyze the cell line data,
and dose dependencies were tested by trend analysis. Grip strength, and
tumor growth for both xenograft and genetically engineered mouse
models were analyzed by using mixed effect model, accounting for the
association of the same measure at different time points from the same
mouse. These models included treatment and time of the treatment as
fixed factors, and the intercept of an individual mouse was considered as
a random effect. Tumor weights were compared by using ANOVA, and
percent of Ki67 immunopositivity and percent tumor areas were
analyzed by 2-sample t tests. The survival functions were estimated by
using Kaplan-Meier method, and the significant difference between
survival probabilities among treatment groups was compared by
log-rank tests. To test the association between treatment and the
distribution of muscle fiber size, muscle fibers were dichotomized into
two categories according to the ranges of the cross-sectional area
(0-1800 μm2, N1800 μm2).We averaged the numbers of fibers of each
range for each group and then used χ2 to test the association.Results
Potent Antiproliferative Effects of AR-42 in Human Pancreatic
Cancer Cell Lines by Targeting Signaling Effectors
Associated with the Regulation of Cell Survival and Cell
Cycle Progression
Six human pancreatic cancer cell lines (AsPC-1, SW1990,
BxPC-3, COLO-357, MiaPaCa-2, and PANC-1) were exposed to
different concentrations of AR-42 for 72 hours, and cell viability was
assessed with MTT assays. Among these cell lines, AsPC-1, SW1990,
BxPC-3, COLO-357, and MiaPaCa-2 showed dose-dependent
suppression of growth at sub-μM concentrations of AR-42, with
IC50 values ranging from 0.4 to 0.5 μM (Figure 1, A–E).
Pharmokinetic analysis of AR-42 in vivo demonstrates a Cmax of
14.7 μM, well above the antiproliferative doses seen in vitro [28]. In
contrast, PANC-1 cells were more resistant to AR-42 (IC50, 6 μM)
(Figure 1F). Nonetheless, AR-42 induced significant dose-dependent
decreases in cell viability in all cell lines tested (all P values b .0001,
trend tests). Western blot analysis of biomarkers of HDAC inhibition
revealed concentration-dependent increases in the abundance of
acetylated histone H3 and the cyclin-dependent kinase inhibitor p21
in all six cell lines examined, confirming HDAC inhibitory effects of
AR-42 (Figure 2). The AR-42–mediated inhibition of cell viability
was, in part, attributable to apoptosis, as evidenced by PARP cleavage,
which was accompanied by parallel changes in the expression/
phosphorylation levels of various apoptosis regulators, including Akt,
the proapoptotic regulator BAK, and the antiapoptotic regulator
Bcl-xL (Figure 2). Changes in these biomarkers were noted in the
AR-42–resistant PANC-1 cells even at low concentrations of AR-42.
In addition, AR-42 reduced the expression of several cell cycle
regulators, including c-Myc and cyclin B1 in all six cell lines and
PCNA, a protein involved in DNA replication, in AsPC-1, BxPC-3,
and MiaPaCa-2 cells. Cell cycle analysis revealed that AR-42 induced
G2/M arrest in AsPC-1, SW1990, BxPC-3, COLO-357, and
PANC-1 cells consistent with the downregulation of cyclin B1
expression observed by Western blot. In MiaPaCa-2 cells, a
prominent increase in treated cells in sub-G1 phase relative to
control cells was observed, indicative of apoptosis (Supplementary
Figure S1).
AR-42 Suppressed AsPC-1 Xenograft Tumor Growth In Vivo
The in vivo efficacy of AR-42 was assessed in a subcutaneous
xenograft tumor model of pancreatic cancer. Female athymic nude
mice bearing established AsPC-1 tumors (mean ± SD, 90.7 ± 9.4 mm3)
were treated with 50 mg/kg AR-42 or vehicle (n = 7 in each group) by
oral gavage every other day. As shown in Figure 3A, AR-42
significantly suppressed AsPC-1 tumor growth. The growth in tumor
volume at each of the time points examined was significantly lower in
the AR-42–treated group than in the vehicle-treated group [7 days,
(P b .05), 14 days (P b .0001), and 21 days (P b .0001) of
treatment], culminating in a 78% reduction in tumor growth at the
study end point. To correlate the suppression of tumor growth with
the observed in vitro results, the effects of AR-42–mediated HDAC
inhibition on representative intratumoral biomarkers of drug activity
were evaluated by Western blotting of tumor lysates collected at the
end of the study. Consistent with the in vitro findings, tumor
suppression was associated with increased acetylation of histone H3
and changes in the expression of the apoptosis regulators BCL-XL
and BAK and the cell cycle regulators c-Myc, PCNA, and cyclin B1
(Figure 3B).
Figure 1. Antiproliferative effects of AR-42 in six different pancreatic cancer cell lines. Human PDAC cell lines (A) AsPC-1, (B) SW1990, (C)
BxPC-3, (D) COLO-357, (E) MiaPaCa-2, and (F) PANC-1 were treated for 72 hours with AR-42 (Arno Therapeutics, Inc., Flemington, NJ). Cell
viability was measured via MTT assay. The data are shown as mean ± SD of n = 6 replicates.
Figure 2. Effects of AR-42 on various biomarkers of apoptosis, HDAC inhibition, and proliferation. Human PDAC cells (AsPC-1, SW1990,
BxPC-3, COLO-357, and PANC-1) were treated with AR-42 for 48 hours at the concentrations indicated, and cell lysates were made for
Western blotting. Immunoblots of markers of HDAC inhibition (A), apoptosis (B), and proliferation and G2 cell cycle arrest (C). β-Actin was
used as a loading control.
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Figure 3. Effects of oral AR-42 in an AsPC-1 subcutaneous xenograft mouse model on tumor suppression and expression of intratumoral
biomarkers of drug activity. Female athymic nude mice (5 weeks of age) were injected subcutaneously with 1 × 106 AsPC-1 cells. As the
tumors became established (90.7 ± 9.4 mm3 [mean ± SD]), mice were treated with 50 mg/kg AR-42 (n = 7) or vehicle (n = 7) by oral
gavage every other day. Tumor volumewasmeasured weekly with calipers, and volumes were calculated with a standard formula: width2
× length x 0.52. (A) AR-42 reduced tumoral volume by 78% after 21 days of treatment (****P b .0001). (B) Effects of HDAC inhibition on
representative intratumoral biomarkers of drug activity evaluated through Western immunoblotting of AsPC-1 tumor homogenates
collected after 21 days of treatment. β-Actin was used as a loading control. Tumor volumes were analyzed by mixed effect model,
incorporating repeated measures for each tumor (from day 0 to 21).
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Pursuant to the above finding, we used the KPfl/flC (LSL-KrasG12D;
Trp53flox/flox;Pdx-1-Cre) mouse model, which recapitulates the func-
tional heterogeneity of human pancreatic cancer [29] to evaluate the
in vivo efficacy of AR-42. Twenty-eight-day-old mice were treated
with vehicle (n = 11) or AR-42 at 25 (n = 7) or 50 mg/kg (n = 11) by
oral gavage every other day until sacrifice (Figure 4A). Ultrasound
measurements of tumor volume demonstrated that AR-42 at
50 mg/kg significantly decreased tumor growth by 55% after 4
weeks of treatment (8 weeks of age) (P b .05) (Figure 4B), which was
paralleled by reductions of 57.4% and 55.8% in the total weights of
tumoral pancreas at the study end point in mice treated with AR-42
at 25 and 50 mg/kg, respectively (P b .0001 for both dosages)
(Figure 4C). Immunohistochemical analysis of pancreatic tumors
showed that treatment with AR-42 significantly decreased the
percent of tumor area (pan-cytokeratin staining) (P b .05) (Figure 4D).
Analysis of pancreatic tumors using immunofluorescence showed that
treatment with AR-42 significantly decreased the percentage of
proliferative tumor cells (P b .001) (Figure 4F) and increased percent
caspase 3 area (P b .05) (Figure 4G).
The Combination of AR-42 withGemcitabine ProlongedOverall
Survival in KPfl/flC Mice Compared to Either Agent Alone
In light of the in vivo efficacy of AR-42 as a single agent, we
assessed the ability of AR-42 to enhance the therapeutic effect of
gemcitabine, a standard-of-care chemotherapeutic agent for pancre-
atic cancer, on the survival of KP fl/flC mice (Figure 5A). As shown,
gemcitabine at 40 (n = 8) or 80 mg/kg (n = 7) (twice weekly, i.p.) and
AR-42 at 25 (n = 8) or 50 mg/kg (n = 12) (q2d, p.o.) significantly
prolonged the overall survival of KP fl/flC mice relative to vehicle
control (n = 16) (P b .05 for all groups) (Figure 5B). The median
survival times for these groups were as follows: vehicle, 59 days;
AR-42: 25 mg/kg, 65 days; 50mg/kg, 65 days; gemcitabine: 40mg/kg,68 days; 80mg/kg, 75 days. The difference in survival between the low-
and high-dose groups of either AR-42 or gemcitabine was not
statistically significant. Therefore, a low-dose metronomic regimen
consisting of every-other-day administration of AR-42 at 25 mg/kg and
twice-weekly administration of gemcitabine at 40 mg/kg was used to
examine the effect of the combination therapy on survival of KP fl/flC
mice (n = 9). As shown, this drug combination significantly prolonged
survival (median survival time, 83 days) relative to that for each single
agent regimen (AR-42, P b .0001; gemcitabine, P b .05).
AR-42 PreservedMuscle Fiber Size and Grip Strength in KPfl/flC
Mice
We recently reported that AR-42 suppressed cancer-induced
muscle wasting in the C-26 colon carcinoma and Lewis lung
carcinoma models of cancer cachexia [23]. Pursuant to this finding,
we examined two indicators of skeletal muscle wasting, muscle fiber
size and grip strength, in KP fl/flC mice treated with either AR-42
(25 mg/kg, q2d) or vehicle as described in the timeline shown in
Figure 5A. Consistent with our previous work, AR-42 preserved
muscle fiber size relative to vehicle, as determined by morphometric
analysis of H&E-stained gastrocnemius muscle (Figure 6, A and B).
The muscles of AR-42–treated mice contained a significantly greater
proportion of fibers with large cross-sectional area (N1800 μm3)
than those of vehicle-treated mice (47.0% vs. 23.1%, P b .001)
(Figure 6B). This finding was consistent with the grossly evident
preservation of muscle size in AR-42–treated mice (Figure 6A and
Supplementary Figure S2). Treatment with AR-42 resulted in an
improvement in grip strength from 4 to 8 weeks of age (P b .05),
whereas vehicle-treated mice showed decrease in grip strength over
the same interval (P b .05). This anticachectic effect was reflected in
the ability of AR-42 to improve grip strength at 8 weeks of age
(4 weeks of treatment) versus vehicle control (P b .01) (Figure 6C).
Furthermore, treatment with AR-42 resulted in decreased expression
of the cachexia biomarker MuRF1 due to HDAC inhibition
Figure 4. Effects of oral AR-42 in a transgenic mouse model of pancreatic cancer. (A) KPfl/flC (LSL-KrasG12D;Trp53flox/flox;Pdx-1-Cre)
genetically engineered mice at 4 weeks of age were treated with AR-42 at the 25- and 50-mg/kg dosage (n = 7 and 11, respectively) or
vehicle (n = 11) by oral gavage every other day for 32 days. (B) Tumor volume was measured in mice using pancreatic ultrasound (Vevo
770) while mice were under anesthesia at weeks 4, 6, and 8. AR-42 (50 mg/kg) decreased the size of tumoral pancreas by 55% at week 8
(*P b .05). (C) Ex vivo pancreatic tumors were weighed postmortem at week 9. AR-42 decreased the total weight of the tumoral pancreas
by 57.4% and 55.8% at the dosage of 25 and 50mg/kg, respectively (****P b .0001). (D) Treatment with AR-42 significantly decreased the
percent tumor area of the pancreas as evidenced by decreased pan-cytokeratin (AE1/AE3) immunostaining (*P b .05). (E)
Immunofluorescence triple staining with pan-cytokeratin, Ki67, and active caspase 3. (F and G) The quantification of Ki67 and active
caspase 3. Tumor weights were compared by using ANOVA; percent of Ki67+, percent tumor areas, and percent caspase 3 area were
analyzed by two-sample t tests (*P b .05; ***P b .001). Note: n.s.: not significant.
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(Figure 6D).
Discussion
Pancreatic cancer is associated with a dismal prognosis with few
therapeutic options. HDAC overexpression has been documented in
a variety of cancers, including pancreatic cancer [30], and therefore
represents a promising target in pancreatic cancer therapy. Here, we
demonstrate the in vitro and in vivo effects of the HDAC inhibitor
AR-42 in pancreatic cancer. Our results show that AR-42 inhibits the
growth of human pancreatic cancer cells at sub-μM concentrations in
association with dose-dependent modulation of apoptotic regulators,
HDAC inhibition, decreased proliferation, and G2 cell cycle arrest.
Moreover, we show that AR-42 suppresses tumor growth in two
mouse models of pancreatic cancer and ameliorates cancer-induced
muscle atrophy.
A major mechanism in the pathogenesis of pancreatic cancer is
evasion of apoptosis and acquisition of a drug-resistant phenotype
[31]. In particular, the antiapoptotic factor BCL-XL is overexpressed
in pancreatic cancer, blocking activation of the intrinsic and extrinsic
apoptosis pathways [32]. Treatment with AR-42 induced
dose-dependent downregulation of BCL-XL at sub-μM concentra-
tions in all cell lines except PANC-1, where downregulation was
noted at a concentration of 2 μM. In addition, AR-42 induced
upregulation of the proapoptotic factor BAK and PARP cleavage atsub-μM doses in all cell lines. The PI3K/Akt pathway is an important
prosurvival pathway in pancreatic cancer cells and is activated by
oncogenic KRAS, as well as through growth factors and cytokines.
Activation of PI3K leads to phosphorylation of Akt and subsequent
antiapoptotic effects and uncontrolled cellular proliferation [31].
Furthermore, mutations in Akt in addition to KRAS mutations may
accelerate PDAC development [33]. Recently, targeting the PI3K/
Akt pathway in combination with blockade of MAPK has been
shown to increase cell cycle arrest and apoptosis in pancreatic cancer
cell lines [34]. We previously reported that AR-42 induces
dephosphorylation of Akt through release of PP1 from PP1-HDAC
complexes independent of histone acetylation [19]. In this study,
AR-42 treatment resulted in dose-dependent downregulation of
phospho-Akt in all cell lines except PANC-1. In addition to
modulation of apoptosis, Akt regulates several transcription factors,
including c-Myc [31], a proto-oncogene that when overexpressed
leads to dysregulation of proliferation, differentiation, and apoptosis.
It is estimated that c-Myc is overexpressed in 20% of all human
cancers, including pancreatic cancer, and has been correlated with
worse survival in pancreatic cancer patients [35]. We show that
AR-42 induced potent downregulation of c-Myc in all cell lines
tested. AR-42 treatment was also associated with decreased expression
of cyclin B1, a regulatory protein involved in the transition from the
G2 to M phase of the cell cycle. Overexpression of cyclin B1 leads to
uncontrolled binding to cyclin-dependent kinases, resulting in
Figure 6. Anticachectic effects of oral AR-42. (A) Upper panel, photogr
limb; lower panel, H&E staining of represented frozen cross-sectiona
(25 mg/kg) or vehicle. (B) The cross-sectional area of muscle fiber di
N1800μm2 in gastrocnemius muscles in KPfl/flC mice treated with AR
(***P b .001, χ2 test). (C) Treatment with AR-42 resulted in a significa
whereas vehicle-treatedmice showed a significant decrease in grip stre
increased in the AR-42–treated group versus vehicle at week 8 in KPfl/
expression of the cachexia biomarker MuRF1 and increased expressio
Figure 5. Kaplan-Meier survival curves. (A) Timelineof gemcitabine and
AR-42 administration. (B) AR-42 alone (25mg/kg [A25], p.o., every other
day, n = 8 and 50 mg/kg [A50] p.o. every other day, n = 12),
gemcitabine alone (40mg/kg [G40] by i.p. injection twiceweekly, n=8
and 80 mg/kg [G80] by i.p. injection twice weekly; n = 7), and the
combination of both gemcitabine and AR-42 (G40 + A25; n = 9)
significantly increased survival in KPC mice compared to mice treated
with vehicle (n = 16). The combination of AR-42 at 25 mg/kg and
gemcitabine at 40 mg/kg significantly increased the median survival
time (83 days) relative to AR-42 (P b .0001) and gemcitabine (P b .05)
alone. Statistical comparison of survival curves was performed with
log-rank test (*P b .05; **P b .01; ****P b .0001).
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the tumor suppressor p53, which occurs in 50% to 75% of pancreatic
cancer patients [37,38]. Mutant p53 has also been implicated in
driving rapid progression of premalignant lesions with KRASG12D
mutations, promoting malignant tumor growth and metastasis [38].
Therefore, AR-42 appears to target pathways downstream of
oncogenic KRAS and those associated with mutations frequently
seen in pancreatic cancer, demonstrating a spectrum of antitumor
activity that is reflected in its broad efficacy against five different
pancreatic cancer cell lines and that suggests its potential clinical
activity against PDAC.
Our data showed that PANC-1 cells were more resistant to AR-42
than the other cell lines tested, which is consistent with previous
reports of PANC-1’s resistance to other HDAC inhibitors, including
SAHA, trichostatin A, and panobinostat [9,11,39]. For instance, it
was reported that SAHA did not inhibit proliferation, had no
significant effect on PARP cleavage or caspase-3, and failed to induce
expression of p21 in PANC-1 cells, leading the authors to conclude
that the major mechanism by which SAHA induces growth arrest in
some pancreatic cancer cell lines is dependent on p21 upregulation
[11]. In our study, however, despite sensitivity to AR-42–induced
upregulation of p21 at sub-μM concentrations and to HDAC
inhibition as indicated by increased acetylated-H3, PANC-1 cells
were markedly more resistant to the antiproliferative effects of AR-42
(IC50 N 2 μM). The lack of Akt dephosphorylation and the need for a
higher dose of AR-42 to downregulate BCL-XL expression in
PANC-1 cells may suggest a mechanism by which this cell line is
more resistant to HDAC inhibitors. Characterizing the molecularaphic images of representative leg skeletal muscles in the right hind
l gastrocnemius muscle fibers of KPfl/flC mice treated with AR-42
ameter is represented as a stacked column. The number of fibers
-42 (25 mg/kg) was significantly greater than vehicle-treated mice
nt improvement in grip strength from week 4 to week 8 (*P b .05),
ngth fromweek 4 toweek 8 (*P b .05). Grip strengthwas significantly
flC mice (**P b .01). (D) Treatment with AR-42 resulted in decreased
n of the HDAC inhibition marker acetylated histone H3.
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patient subpopulations.
These in vitro antiproliferative effects of AR-42 were reflected
in our in vivo studies, in which oral AR-42 suppressed tumor
growth in both the subcutaneous AsPC-1 xenograft tumor model
and the genetically engineered KPfl/flC model of pancreatic
cancer. This tumor suppression was associated with changes in
intratumoral biomarkers that reflected drug effects observed in vitro.
These included proapoptotic changes in the expression of BCL-XL
and BAK and antiproliferative changes in c-Myc, PCNA, and
cyclin B1 expression, which were associated with biomarkers of
HDAC inhibition.
From a translational perspective, AR-42’s antitumor activity in
KP fl/flC mice is noteworthy in that this model was engineered to
harbor genetic lesions in the pancreas that have been shown to
contribute to pancreatic carcinogenesis and progression in people.
Specifically, these mice carry an oncogenic mutation in codon 12 of
KRAS, rendering it constitutively active, and p53 nullizygosity, which
generates rapidly progressing and lethal adenocarcinomas in 100% of
mice by 8 weeks of age [40]. This model recapitulates many aspects of
the progression of PDAC development seen in pancreatic cancer
patients. Equally important is that the combination of AR-42 with
gemcitabine improved the overall survival of KP fl/flCmice over that of
mice treated with either agent alone. This combinatorial effect of
AR-42 and gemcitabine on survival is reminiscent of the findings of a
recent study reporting improved efficacy for the combination of
gemcitabine and nab-paclitaxel [41] and suggests that AR-42 may
provide additional benefit in a regimen combining AR-42,
gemcitabine, and nab-paclitaxel.
Cachexia is a devastating condition that affects the majority of
PDAC patients, resulting in reduced physical and respiratory
function, immunity, chemotherapy response, and overall survival
[42]. In particular, pancreatic cancer patients with cachexia have been
shown to have a significantly reduced survival, and nearly one third of
pancreatic cancer deaths are related to cachexia rather than tumor
burden [43]. Reminiscent of its effects in colon and lung tumor
models of cancer cachexia [23], our data show that AR-42 can
improve muscle function and mass, as determined by measurements
of grip strength and muscle fiber size, respectively, suggesting that
AR-42 also exhibits anticachectic activity in a model of pancreatic
cancer. Future studies will more thoroughly characterize cachexia and
the ability of AR-42 to diminish muscle wasting in pancreatic cancer.
Conclusion
In conclusion, this study demonstrates the efficacy of AR-42 in
suppressing pancreatic tumor growth through modulation of
apoptosis, HDAC inhibition, and cell growth and proliferation
and, in combination with the standard of care gemcitabine, in
prolonging overall survival in a spontaneous tumor model of
pancreatic carcinogenesis. Together, these results suggest that the
inclusion of AR-42 in therapeutic regimens represents a promising
strategy for the treatment of pancreatic cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.10.003.
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